Vistin Pharma Past Earnings Performance
Past criteria checks 5/6
Vistin Pharma has been growing earnings at an average annual rate of 44.2%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 15.9% per year. Vistin Pharma's return on equity is 18.9%, and it has net margins of 12.8%.
Key information
44.2%
Earnings growth rate
44.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 15.9% |
| Return on equity | 18.9% |
| Net Margin | 12.8% |
| Next Earnings Update | 23 Aug 2024 |
Recent past performance updates
Recent updates
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26Revenue & Expenses BreakdownBeta
How Vistin Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 441 | 56 | 94 | 0 |
| 31 Dec 23 | 438 | 46 | 82 | 0 |
| 30 Sep 23 | 439 | 45 | 79 | 0 |
| 30 Jun 23 | 410 | 14 | 74 | 0 |
| 31 Mar 23 | 373 | 7 | 71 | 0 |
| 31 Dec 22 | 305 | -5 | 70 | 0 |
| 30 Sep 22 | 272 | -15 | 71 | 0 |
| 30 Jun 22 | 243 | -7 | 69 | 0 |
| 31 Mar 22 | 241 | 1 | 66 | 0 |
| 31 Dec 21 | 279 | 25 | 65 | 0 |
| 30 Sep 21 | 265 | 26 | 63 | 0 |
| 30 Jun 21 | 257 | 30 | 64 | 0 |
| 31 Mar 21 | 263 | 43 | 82 | 0 |
| 31 Dec 20 | 254 | -97 | 64 | 0 |
| 30 Sep 20 | 246 | -102 | 63 | 0 |
| 30 Jun 20 | 259 | -46 | 63 | 0 |
| 31 Mar 20 | 247 | -67 | 46 | 0 |
| 31 Dec 19 | 228 | 66 | 61 | 0 |
| 30 Sep 19 | 212 | 4 | 70 | 0 |
| 30 Jun 19 | 196 | -59 | 69 | 0 |
| 31 Mar 19 | 190 | -72 | 69 | 0 |
| 31 Dec 18 | 201 | -68 | 70 | 0 |
| 30 Sep 18 | 200 | -16 | 70 | 0 |
| 30 Jun 18 | 194 | -8 | 65 | 0 |
| 31 Mar 18 | 186 | 8 | 62 | 0 |
| 31 Dec 17 | 175 | 5 | 58 | 0 |
| 30 Sep 17 | 168 | 10 | 50 | 0 |
| 30 Jun 17 | 160 | 7 | 49 | 0 |
| 31 Mar 17 | 170 | 14 | 48 | 0 |
| 31 Dec 16 | 173 | 16 | 47 | 0 |
| 30 Sep 16 | 393 | 40 | 105 | 0 |
| 30 Jun 16 | 446 | 46 | 123 | 0 |
| 31 Dec 15 | 376 | 33 | 108 | 0 |
| 31 Dec 14 | 361 | -62 | 96 | 0 |
| 31 Dec 13 | 347 | 8 | 94 | 0 |
Quality Earnings: VISTN has high quality earnings.
Growing Profit Margin: VISTN's current net profit margins (12.8%) are higher than last year (2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VISTN has become profitable over the past 5 years, growing earnings by 44.2% per year.
Accelerating Growth: VISTN's earnings growth over the past year (654.9%) exceeds its 5-year average (44.2% per year).
Earnings vs Industry: VISTN earnings growth over the past year (654.9%) exceeded the Pharmaceuticals industry 2.6%.
Return on Equity
High ROE: VISTN's Return on Equity (18.9%) is considered low.